PropertyValue
?:abstract
  • To determine the effect renin-angiotensin system blockers on the outcome in patients with hypertension and concurrent COVID-19 infection, we searched PubMed, the Cochrane Library, and Google Scholar for relevant articles. Twelve studies with a total of 16,101 patients met the inclusion criteria. The mortality rate among the users of angiotensin converting enzyme inhibitors or angiotensin receptor blockers was 12.15% and in non-users it was 14.56% (risk ratio 0.70, 95% CI [0.53-0.91], P < 0.007). There was no difference in the risk of death between the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers (risk ratio 1.09, 95% CI [0.90 -1.32]). We conclude that the use of angiotensin converting enzyme inhibitors and angiotensin receptor blockers improves mortality in patients with hypertension and concurrent COVID-19 infection, without a significant difference between ACEIs and ARBs in this population.
?:creator
?:doi
?:doi
  • 10.1177/1074248420947628
?:journal
  • J_Cardiovasc_Pharmacol_Ther
?:license
  • cc-by
?:pdf_json_files
  • document_parses/pdf_json/06e93fd31bd5f8f6f8c247abbe996d73d60bcc24.json
?:pmc_json_files
  • document_parses/pmc_json/PMC7404086.xml.json
?:pmcid
?:pmid
?:pmid
  • 32748634.0
?:publication_isRelatedTo_Disease
?:sha_id
?:source
  • Medline; PMC
?:title
  • Renin-Angiotensin System Blockade and Mortality in Patients With Hypertension and COVID-19 Infection
?:type
?:year
  • 2020-08-04

Metadata

Anon_0  
expand all